
    
      All subjects in each dose-group will visit 1 month* (visit 5, 1 monthÂ±5 days) after
      administration of investigational product to evaluate dose limit toxicity (DLT) and determine
      whether to drop or proceed to next dose level.

      Total 5 visit (1week, 1 month, 2 months, 3 months, 6 months) until 6 months after
      administration of investigational product is planned to assess safety through vial sign,
      laboratory tests, and exploratory efficacy of IP will be assessed through Western Ontario and
      McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS) and
      International Knee Documentation Committee (IKDC) subjective knee evaluation.
    
  